ID   PGK1_HUMAN              Reviewed;         417 AA.
AC   P00558; A8K4W6; B7Z7A9; Q5J7W1; Q6IBT6; Q8NI87;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 198.
DE   RecName: Full=Phosphoglycerate kinase 1;
DE            EC=2.7.2.3;
DE   AltName: Full=Cell migration-inducing gene 10 protein;
DE   AltName: Full=Primer recognition protein 2;
DE            Short=PRP 2;
GN   Name=PGK1; Synonyms=PGKA; ORFNames=MIG10, OK/SW-cl.110;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6188151; DOI=10.1073/pnas.80.2.472;
RA   Michelson A.M., Markham A.F., Orkin S.H.;
RT   "Isolation and DNA sequence of a full-length cDNA clone for human X
RT   chromosome-encoded phosphoglycerate kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:472-476(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2995995; DOI=10.1073/pnas.82.20.6965;
RA   Michelson A.M., Blake C.C., Evans S.T., Orkin S.H.;
RT   "Structure of the human phosphoglycerate kinase gene and the intron-
RT   mediated evolution and dispersal of the nucleotide-binding domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6965-6969(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kim J.W.;
RT   "Identification of a human migration-inducing gene 10 (MIG10).";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-
RT   reactive CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cerebellum, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21.
RX   PubMed=6099325; DOI=10.1016/0378-1119(84)90016-7;
RA   Singer-Sam J., Keith D.H., Tani K., Simmer R.L., Shively L.,
RA   Lindsay S., Yoshida A., Riggs A.D.;
RT   "Sequence of the promoter region of the gene for human X-linked 3-
RT   phosphoglycerate kinase].";
RL   Gene 32:409-417(1984).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-14.
RX   PubMed=2814502; DOI=10.1126/science.2814502;
RA   Pfeifer G.P., Steigerwald S.D., Mueller P.R., Wold B., Riggs A.D.;
RT   "Genomic sequencing and methylation analysis by ligation mediated
RT   PCR.";
RL   Science 246:810-813(1989).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-417.
RC   TISSUE=Erythrocyte;
RX   PubMed=7391027;
RA   Huang I.-Y., Welch C.D., Yoshida A.;
RT   "Complete amino acid sequence of human phosphoglycerate kinase.
RT   Cyanogen bromide peptides and complete amino acid sequence.";
RL   J. Biol. Chem. 255:6412-6420(1980).
RN   [13]
RP   PROTEIN SEQUENCE OF 23-30; 76-86; 107-123; 157-171; 200-216; 221-264;
RP   280-297; 333-350; 366-382 AND 389-417, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [14]
RP   PARTIAL PROTEIN SEQUENCE, AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=2324090;
RA   Jindal H.K., Vishwanatha J.K.;
RT   "Functional identity of a primer recognition protein as
RT   phosphoglycerate kinase.";
RL   J. Biol. Chem. 265:6540-6543(1990).
RN   [15]
RP   REVIEW ON VARIANTS.
RX   PubMed=9075577; DOI=10.1006/bcmd.1996.0108;
RA   Yoshida A.;
RT   "Hematologically important mutations: molecular abnormalities of
RT   phosphoglycerate kinase.";
RL   Blood Cells Mol. Dis. 22:265-267(1996).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-196, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-11; LYS-48; LYS-75; LYS-86;
RP   LYS-97; LYS-131; LYS-146; LYS-199; LYS-267 AND LYS-291, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   MALONYLATION AT LYS-131.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-4 AND SER-203,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [28]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=26677959; DOI=10.1093/humrep/dev301;
RA   Liu X.X., Zhang H., Shen X.F., Liu F.J., Liu J., Wang W.J.;
RT   "Characteristics of testis-specific phosphoglycerate kinase 2 and its
RT   association with human sperm quality.";
RL   Hum. Reprod. 31:273-279(2016).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH
RP   PHOSPHOGLYCERATE; L-ADP; D-ADP; L-CDP AND D-CDP, AND SUBSTRATE-BINDING
RP   SITES.
RX   PubMed=18463139; DOI=10.1093/nar/gkn212;
RA   Gondeau C., Chaloin L., Lallemand P., Roy B., Perigaud C., Barman T.,
RA   Varga A., Vas M., Lionne C., Arold S.T.;
RT   "Molecular basis for the lack of enantioselectivity of human 3-
RT   phosphoglycerate kinase.";
RL   Nucleic Acids Res. 36:3620-3629(2008).
RN   [30]
RP   VARIANT PGK1D LYS-191 DEL.
RX   PubMed=8673469; DOI=10.1006/bcmd.1995.0020;
RA   Yoshida A., Twele T.W., Dave V., Beutler E.;
RT   "Molecular abnormality of a phosphoglycerate kinase variant (PGK-
RT   Alabama).";
RL   Blood Cells Mol. Dis. 21:179-181(1995).
RN   [31]
RP   VARIANTS PGK1D VAL-164 AND ASN-315.
RX   PubMed=8043870;
RA   Cohen-Solal M., Valentin C., Plassa F., Guillemin G., Danze F.,
RA   Jaisson F., Rosa R.;
RT   "Identification of new mutations in two phosphoglycerate kinase (PGK)
RT   variants expressing different clinical syndromes: PGK Creteil and PGK
RT   Amiens.";
RL   Blood 84:898-903(1994).
RN   [32]
RP   VARIANT PGK1D ALA-252.
RX   PubMed=8615693; DOI=10.1006/abbi.1996.0089;
RA   Ookawara T., Dave V., Willems P., Martin J.J., de Barsy T.,
RA   Matthys E., Yoshida A.;
RT   "Retarded and aberrant splicings caused by single exon mutation in a
RT   phosphoglycerate kinase variant.";
RL   Arch. Biochem. Biophys. 327:35-40(1996).
RN   [33]
RP   VARIANT PGK1D VAL-285.
RX   PubMed=9744480;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:4<280::AID-HUMU10>3.0.CO;2-V;
RA   Valentin C., Birgens H., Craescu C.T., Broedum-Nielsen K.,
RA   Cohen-Solal M.;
RT   "A phosphoglycerate kinase mutant (PGK Herlev; D285V) in a Danish
RT   patient with isolated chronic hemolytic anemia: mechanism of mutation
RT   and structure-function relationships.";
RL   Hum. Mutat. 12:280-287(1998).
RN   [34]
RP   VARIANT PGK1D PRO-88.
RX   PubMed=2001457;
RA   Maeda M., Yoshida A.;
RT   "Molecular defect of a phosphoglycerate kinase variant (PGK-Matsue)
RT   associated with hemolytic anemia: Leu-->Pro substitution caused by
RT   T/A-->C/G transition in exon 3.";
RL   Blood 77:1348-1352(1991).
RN   [35]
RP   VARIANT PGK1D ARG-316.
RX   PubMed=1586722;
RA   Maeda M., Bawle E.V., Kulkarni R., Beutler E., Yoshida A.;
RT   "Molecular abnormalities of a phosphoglycerate kinase variant
RT   generated by spontaneous mutation.";
RL   Blood 79:2759-2762(1992).
RN   [36]
RP   VARIANT MUNCHEN ASN-268.
RX   PubMed=7391028;
RA   Fujii H., Krietsch W.K.G., Yoshida A.;
RT   "A single amino acid substitution (Asp leads to Asn) in a
RT   phosphoglycerate kinase variant (PGK Munchen) associated with enzyme
RT   deficiency.";
RL   J. Biol. Chem. 255:6421-6423(1980).
RN   [37]
RP   VARIANT MUNCHEN ASN-268, AND VARIANT ASN-352.
RX   PubMed=7440217; DOI=10.3109/03630268008997730;
RA   Huang I.-Y., Fujii H., Yoshida A.;
RT   "Structure and function of normal and variant human phosphoglycerate
RT   kinase.";
RL   Hemoglobin 4:601-609(1980).
RN   [38]
RP   VARIANT PGK1D VAL-158.
RX   PubMed=1547346;
RA   Fujii H., Kanno H., Hirono A., Shiomura T., Miwa S.;
RT   "A single amino acid substitution (157 Gly-->Val) in a
RT   phosphoglycerate kinase variant (PGK Shizuoka) associated with chronic
RT   hemolysis and myoglobinuria.";
RL   Blood 79:1582-1585(1992).
RN   [39]
RP   VARIANT PGK1D MET-266.
RX   PubMed=6941312; DOI=10.1073/pnas.78.4.2587;
RA   Fujii H., Chen S.-H., Akatsuka J., Miwa S., Yoshida A.;
RT   "Use of cultured lymphoblastoid cells for the study of abnormal
RT   enzymes: molecular abnormality of a phosphoglycerate kinase variant
RT   associated with hemolytic anemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:2587-2590(1981).
RN   [40]
RP   VARIANT PGK1D PRO-206.
RX   PubMed=6933565; DOI=10.1073/pnas.77.9.5461;
RA   Fujii H., Yoshida A.;
RT   "Molecular abnormality of phosphoglycerate kinase-Uppsala associated
RT   with chronic nonspherocytic hemolytic anemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:5461-5465(1980).
CC   -!- FUNCTION: In addition to its role as a glycolytic enzyme, it seems
CC       that PGK-1 acts as a polymerase alpha cofactor protein (primer
CC       recognition protein) (PubMed:2324090). May play a role in sperm
CC       motility (PubMed:26677959). {ECO:0000269|PubMed:2324090,
CC       ECO:0000269|PubMed:26677959}.
CC   -!- CATALYTIC ACTIVITY: ATP + 3-phospho-D-glycerate = ADP + 3-phospho-
CC       D-glyceroyl phosphate.
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 2/5.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:18463139}.
CC   -!- INTERACTION:
CC       P04406:GAPDH; NbExp=2; IntAct=EBI-709599, EBI-354056;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P00558-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P00558-2; Sequence=VSP_056159;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in spermatogonia. Localized
CC       on the principle piece in the sperm (at protein level). Expression
CC       significantly decreased in the testis of elderly men.
CC       {ECO:0000269|PubMed:26677959}.
CC   -!- DISEASE: Phosphoglycerate kinase 1 deficiency (PGK1D)
CC       [MIM:300653]: A condition with a highly variable clinical
CC       phenotype that includes hemolytic anemia, rhabdomyolysis, myopathy
CC       and neurologic involvement. Patients can express one or more of
CC       these manifestations. {ECO:0000269|PubMed:1547346,
CC       ECO:0000269|PubMed:1586722, ECO:0000269|PubMed:2001457,
CC       ECO:0000269|PubMed:6933565, ECO:0000269|PubMed:6941312,
CC       ECO:0000269|PubMed:8043870, ECO:0000269|PubMed:8615693,
CC       ECO:0000269|PubMed:8673469, ECO:0000269|PubMed:9744480}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the phosphoglycerate kinase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=PGK1";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Phosphoglycerate kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Phosphoglycerate_kinase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; V00572; CAA23835.1; -; mRNA.
DR   EMBL; L00160; AAA60078.1; -; mRNA.
DR   EMBL; M11968; AAA60079.1; -; Genomic_DNA.
DR   EMBL; M11958; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11959; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11960; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11961; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11962; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11963; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11964; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11965; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11966; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; M11967; AAA60079.1; JOINED; Genomic_DNA.
DR   EMBL; AY423725; AAS00488.1; -; mRNA.
DR   EMBL; AB062432; BAB93495.1; -; mRNA.
DR   EMBL; AK291081; BAF83770.1; -; mRNA.
DR   EMBL; AK301740; BAH13545.1; -; mRNA.
DR   EMBL; AK312280; BAG35209.1; -; mRNA.
DR   EMBL; CR456716; CAG32997.1; -; mRNA.
DR   EMBL; AL049589; CAI42951.1; -; Genomic_DNA.
DR   EMBL; CH471104; EAW98604.1; -; Genomic_DNA.
DR   EMBL; BC023234; AAH23234.1; -; mRNA.
DR   EMBL; BC103752; AAI03753.1; -; mRNA.
DR   EMBL; BC104837; AAI04838.1; -; mRNA.
DR   EMBL; BC113568; AAI13569.1; -; mRNA.
DR   EMBL; M34017; AAA60103.1; -; Genomic_DNA.
DR   CCDS; CCDS14438.1; -. [P00558-1]
DR   PIR; I59050; KIHUG.
DR   RefSeq; NP_000282.1; NM_000291.3. [P00558-1]
DR   UniGene; Hs.78771; -.
DR   PDB; 2WZB; X-ray; 1.47 A; A=2-417.
DR   PDB; 2WZC; X-ray; 1.50 A; A=2-417.
DR   PDB; 2WZD; X-ray; 1.56 A; A=1-417.
DR   PDB; 2X13; X-ray; 1.74 A; A=2-417.
DR   PDB; 2X14; X-ray; 1.90 A; A=2-417.
DR   PDB; 2X15; X-ray; 2.10 A; A=2-417.
DR   PDB; 2XE6; X-ray; 1.74 A; A=1-417.
DR   PDB; 2XE7; X-ray; 2.20 A; A=1-417.
DR   PDB; 2XE8; X-ray; 1.79 A; A=1-417.
DR   PDB; 2Y3I; X-ray; 2.90 A; A/D=1-416.
DR   PDB; 2YBE; X-ray; 2.00 A; A=1-417.
DR   PDB; 2ZGV; X-ray; 2.00 A; A=1-417.
DR   PDB; 3C39; X-ray; 1.85 A; A/B=1-417.
DR   PDB; 3C3A; X-ray; 2.30 A; A/B=1-417.
DR   PDB; 3C3B; X-ray; 1.80 A; A/B=1-417.
DR   PDB; 3C3C; X-ray; 2.40 A; A/B=1-417.
DR   PDB; 3ZOZ; X-ray; 1.95 A; A=1-417.
DR   PDB; 4AXX; X-ray; 1.74 A; A=1-417.
DR   PDB; 4O33; X-ray; 2.10 A; A=1-417.
DR   PDBsum; 2WZB; -.
DR   PDBsum; 2WZC; -.
DR   PDBsum; 2WZD; -.
DR   PDBsum; 2X13; -.
DR   PDBsum; 2X14; -.
DR   PDBsum; 2X15; -.
DR   PDBsum; 2XE6; -.
DR   PDBsum; 2XE7; -.
DR   PDBsum; 2XE8; -.
DR   PDBsum; 2Y3I; -.
DR   PDBsum; 2YBE; -.
DR   PDBsum; 2ZGV; -.
DR   PDBsum; 3C39; -.
DR   PDBsum; 3C3A; -.
DR   PDBsum; 3C3B; -.
DR   PDBsum; 3C3C; -.
DR   PDBsum; 3ZOZ; -.
DR   PDBsum; 4AXX; -.
DR   PDBsum; 4O33; -.
DR   ProteinModelPortal; P00558; -.
DR   SMR; P00558; -.
DR   BioGrid; 111251; 94.
DR   DIP; DIP-33679N; -.
DR   IntAct; P00558; 38.
DR   MINT; MINT-1131047; -.
DR   STRING; 9606.ENSP00000362413; -.
DR   ChEMBL; CHEMBL2096677; -.
DR   DrugBank; DB04510; 3-Phosphoglyceric Acid.
DR   DrugBank; DB00709; Lamivudine.
DR   iPTMnet; P00558; -.
DR   PhosphoSitePlus; P00558; -.
DR   SwissPalm; P00558; -.
DR   BioMuta; PGK1; -.
DR   DMDM; 52788229; -.
DR   DOSAC-COBS-2DPAGE; P00558; -.
DR   OGP; P00558; -.
DR   REPRODUCTION-2DPAGE; IPI00169383; -.
DR   REPRODUCTION-2DPAGE; P00558; -.
DR   UCD-2DPAGE; P00558; -.
DR   EPD; P00558; -.
DR   PaxDb; P00558; -.
DR   PeptideAtlas; P00558; -.
DR   PRIDE; P00558; -.
DR   TopDownProteomics; P00558-1; -. [P00558-1]
DR   DNASU; 5230; -.
DR   Ensembl; ENST00000373316; ENSP00000362413; ENSG00000102144. [P00558-1]
DR   GeneID; 5230; -.
DR   KEGG; hsa:5230; -.
DR   CTD; 5230; -.
DR   DisGeNET; 5230; -.
DR   GeneCards; PGK1; -.
DR   HGNC; HGNC:8896; PGK1.
DR   HPA; CAB010065; -.
DR   HPA; HPA045385; -.
DR   MalaCards; PGK1; -.
DR   MIM; 300653; phenotype.
DR   MIM; 311800; gene.
DR   neXtProt; NX_P00558; -.
DR   OpenTargets; ENSG00000102144; -.
DR   Orphanet; 713; Glycogen storage disease due to phosphoglycerate kinase 1 deficiency.
DR   PharmGKB; PA33234; -.
DR   eggNOG; KOG1367; Eukaryota.
DR   eggNOG; COG0126; LUCA.
DR   GeneTree; ENSGT00390000008820; -.
DR   HOGENOM; HOG000227107; -.
DR   HOVERGEN; HBG008177; -.
DR   InParanoid; P00558; -.
DR   KO; K00927; -.
DR   OMA; IKHCLDH; -.
DR   OrthoDB; EOG091G08S6; -.
DR   PhylomeDB; P00558; -.
DR   TreeFam; TF300489; -.
DR   BioCyc; MetaCyc:HS02359-MONOMER; -.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P00558; -.
DR   UniPathway; UPA00109; UER00185.
DR   ChiTaRS; PGK1; human.
DR   EvolutionaryTrace; P00558; -.
DR   GeneWiki; PGK1; -.
DR   GenomeRNAi; 5230; -.
DR   PRO; PR:P00558; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102144; -.
DR   CleanEx; HS_PGK1; -.
DR   ExpressionAtlas; P00558; baseline and differential.
DR   Genevisible; P00558; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:CAFA.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0004618; F:phosphoglycerate kinase activity; IMP:CAFA.
DR   GO; GO:0047134; F:protein-disulfide reductase activity; IMP:CAFA.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:CAFA.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IMP:CAFA.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:CAFA.
DR   GO; GO:0016310; P:phosphorylation; ISS:UniProtKB.
DR   GO; GO:0031639; P:plasminogen activation; IMP:CAFA.
DR   CDD; cd00318; Phosphoglycerate_kinase; 1.
DR   Gene3D; 3.40.50.1260; -; 2.
DR   HAMAP; MF_00145; Phosphoglyc_kinase; 1.
DR   InterPro; IPR001576; Phosphoglycerate_kinase.
DR   InterPro; IPR015911; Phosphoglycerate_kinase_CS.
DR   InterPro; IPR015824; Phosphoglycerate_kinase_N.
DR   PANTHER; PTHR11406; PTHR11406; 1.
DR   Pfam; PF00162; PGK; 1.
DR   PIRSF; PIRSF000724; Pgk; 1.
DR   PRINTS; PR00477; PHGLYCKINASE.
DR   SUPFAM; SSF53748; SSF53748; 1.
DR   PROSITE; PS00111; PGLYCERATE_KINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Glycolysis; Hereditary hemolytic anemia; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:7391027}.
FT   CHAIN         2    417       Phosphoglycerate kinase 1.
FT                                /FTId=PRO_0000145831.
FT   NP_BIND     373    376       ATP.
FT   REGION       24     26       Substrate binding.
FT   REGION       63     66       Substrate binding.
FT   BINDING      39     39       Substrate.
FT   BINDING     123    123       Substrate.
FT   BINDING     171    171       Substrate.
FT   BINDING     220    220       ATP.
FT   BINDING     313    313       ATP; via carbonyl oxygen.
FT   BINDING     344    344       ATP.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES       4      4       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES       6      6       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P09411}.
FT   MOD_RES      11     11       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      48     48       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      48     48       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P09411}.
FT   MOD_RES      75     75       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      76     76       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P09411}.
FT   MOD_RES      86     86       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      91     91       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P09411}.
FT   MOD_RES      97     97       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     131    131       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     131    131       N6-malonyllysine; alternate.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     146    146       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     191    191       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P09411}.
FT   MOD_RES     196    196       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     199    199       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     203    203       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     267    267       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     291    291       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     361    361       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P09411}.
FT   VAR_SEQ       1     28       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056159.
FT   VARIANT      88     88       L -> P (in PGK1D; with congenital non-
FT                                spherocytic anemia; variant Matsue;
FT                                dbSNP:rs137852531).
FT                                {ECO:0000269|PubMed:2001457}.
FT                                /FTId=VAR_006076.
FT   VARIANT     158    158       G -> V (in PGK1D; with chronic hemolytic
FT                                anemia; variant Shizuoka;
FT                                dbSNP:rs137852532).
FT                                {ECO:0000269|PubMed:1547346}.
FT                                /FTId=VAR_006077.
FT   VARIANT     164    164       D -> V (in PGK1D; with chronic hemolytic
FT                                anemia and mental retardation; variant
FT                                Amiens; dbSNP:rs137852538).
FT                                {ECO:0000269|PubMed:8043870}.
FT                                /FTId=VAR_006078.
FT   VARIANT     191    191       Missing (in PGK1D; with chronic hemolytic
FT                                anemia; variant Alabama).
FT                                {ECO:0000269|PubMed:8673469}.
FT                                /FTId=VAR_006079.
FT   VARIANT     206    206       R -> P (in PGK1D; with chronic hemolytic
FT                                anemia; variant Uppsala;
FT                                dbSNP:rs137852529).
FT                                {ECO:0000269|PubMed:6933565}.
FT                                /FTId=VAR_006080.
FT   VARIANT     252    252       E -> A (in PGK1D; with chronic hemolytic
FT                                anemia; variant Antwerp).
FT                                {ECO:0000269|PubMed:8615693}.
FT                                /FTId=VAR_006081.
FT   VARIANT     266    266       V -> M (in PGK1D; with chronic non-
FT                                spherocytic hemolytic anemia; variant
FT                                Tokyo; dbSNP:rs431905501).
FT                                {ECO:0000269|PubMed:6941312}.
FT                                /FTId=VAR_006082.
FT   VARIANT     268    268       D -> N (in Munchen; 21% of activity;
FT                                dbSNP:rs137852528).
FT                                {ECO:0000269|PubMed:7391028,
FT                                ECO:0000269|PubMed:7440217}.
FT                                /FTId=VAR_006083.
FT   VARIANT     285    285       D -> V (in PGK1D; with chronic hemolytic
FT                                anemia; variant Herlev; 50% of activity;
FT                                dbSNP:rs137852535).
FT                                {ECO:0000269|PubMed:9744480}.
FT                                /FTId=VAR_006084.
FT   VARIANT     315    315       D -> N (in PGK1D; with rhabdomyolysis;
FT                                variant Creteil).
FT                                {ECO:0000269|PubMed:8043870}.
FT                                /FTId=VAR_006085.
FT   VARIANT     316    316       C -> R (in PGK1D; with chronic hemolytic
FT                                anemia; variant Michigan;
FT                                dbSNP:rs137852533).
FT                                {ECO:0000269|PubMed:1586722}.
FT                                /FTId=VAR_006086.
FT   VARIANT     352    352       T -> N (in dbSNP:rs137852530).
FT                                {ECO:0000269|PubMed:7440217}.
FT                                /FTId=VAR_006087.
FT   CONFLICT     39     39       Missing (in Ref. 12; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    370    370       I -> T (in Ref. 6; CAG32997).
FT                                {ECO:0000305}.
FT   STRAND        4      6       {ECO:0000244|PDB:3C3C}.
FT   HELIX         9     11       {ECO:0000244|PDB:2WZB}.
FT   STRAND       18     22       {ECO:0000244|PDB:2WZB}.
FT   STRAND       29     32       {ECO:0000244|PDB:3C3A}.
FT   STRAND       33     35       {ECO:0000244|PDB:2WZB}.
FT   HELIX        38     52       {ECO:0000244|PDB:2WZB}.
FT   STRAND       56     61       {ECO:0000244|PDB:2WZB}.
FT   HELIX        73     76       {ECO:0000244|PDB:2WZB}.
FT   HELIX        79     89       {ECO:0000244|PDB:2WZB}.
FT   STRAND       94     97       {ECO:0000244|PDB:3C3B}.
FT   STRAND       99    101       {ECO:0000244|PDB:2WZB}.
FT   HELIX       102    109       {ECO:0000244|PDB:2WZB}.
FT   STRAND      115    118       {ECO:0000244|PDB:2WZB}.
FT   HELIX       122    124       {ECO:0000244|PDB:2WZB}.
FT   TURN        126    130       {ECO:0000244|PDB:2WZB}.
FT   STRAND      131    133       {ECO:0000244|PDB:2XE8}.
FT   STRAND      135    137       {ECO:0000244|PDB:3C3A}.
FT   STRAND      139    141       {ECO:0000244|PDB:2XE6}.
FT   HELIX       144    156       {ECO:0000244|PDB:2WZB}.
FT   STRAND      159    163       {ECO:0000244|PDB:2WZB}.
FT   HELIX       166    168       {ECO:0000244|PDB:2WZB}.
FT   HELIX       174    177       {ECO:0000244|PDB:2WZB}.
FT   STRAND      184    186       {ECO:0000244|PDB:2WZB}.
FT   HELIX       188    202       {ECO:0000244|PDB:2WZB}.
FT   STRAND      206    212       {ECO:0000244|PDB:2WZB}.
FT   HELIX       217    220       {ECO:0000244|PDB:2WZB}.
FT   HELIX       221    223       {ECO:0000244|PDB:2WZB}.
FT   HELIX       224    227       {ECO:0000244|PDB:2WZB}.
FT   TURN        228    230       {ECO:0000244|PDB:2WZB}.
FT   STRAND      232    236       {ECO:0000244|PDB:2WZB}.
FT   HELIX       238    240       {ECO:0000244|PDB:2WZB}.
FT   HELIX       241    249       {ECO:0000244|PDB:2WZB}.
FT   HELIX       260    263       {ECO:0000244|PDB:2WZB}.
FT   HELIX       266    275       {ECO:0000244|PDB:2WZB}.
FT   STRAND      279    281       {ECO:0000244|PDB:2WZB}.
FT   STRAND      285    293       {ECO:0000244|PDB:2WZB}.
FT   STRAND      298    302       {ECO:0000244|PDB:2WZB}.
FT   TURN        303    305       {ECO:0000244|PDB:2WZB}.
FT   STRAND      312    316       {ECO:0000244|PDB:2WZB}.
FT   HELIX       318    330       {ECO:0000244|PDB:2WZB}.
FT   STRAND      332    338       {ECO:0000244|PDB:2WZB}.
FT   HELIX       346    348       {ECO:0000244|PDB:2WZB}.
FT   HELIX       350    364       {ECO:0000244|PDB:2WZB}.
FT   STRAND      368    373       {ECO:0000244|PDB:2WZB}.
FT   HELIX       376    382       {ECO:0000244|PDB:2WZB}.
FT   STRAND      388    394       {ECO:0000244|PDB:2WZB}.
FT   HELIX       397    404       {ECO:0000244|PDB:2WZB}.
FT   HELIX       409    412       {ECO:0000244|PDB:2WZB}.
SQ   SEQUENCE   417 AA;  44615 MW;  B5DFC7B5FA01767C CRC64;
     MSLSNKLTLD KLDVKGKRVV MRVDFNVPMK NNQITNNQRI KAAVPSIKFC LDNGAKSVVL
     MSHLGRPDGV PMPDKYSLEP VAVELKSLLG KDVLFLKDCV GPEVEKACAN PAAGSVILLE
     NLRFHVEEEG KGKDASGNKV KAEPAKIEAF RASLSKLGDV YVNDAFGTAH RAHSSMVGVN
     LPQKAGGFLM KKELNYFAKA LESPERPFLA ILGGAKVADK IQLINNMLDK VNEMIIGGGM
     AFTFLKVLNN MEIGTSLFDE EGAKIVKDLM SKAEKNGVKI TLPVDFVTAD KFDENAKTGQ
     ATVASGIPAG WMGLDCGPES SKKYAEAVTR AKQIVWNGPV GVFEWEAFAR GTKALMDEVV
     KATSRGCITI IGGGDTATCC AKWNTEDKVS HVSTGGGASL ELLEGKVLPG VDALSNI
//
